SXTP
60 Degrees Pharmaceuticals, Inc.
There isn't enough reported data to score SXTP yet.
SXTP Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
SXTP's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
SXTP PE Valuation
SXTP has no meaningful PE right now: it lost money over the past year.
SXTP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SXTP's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
SXTP Earnings Per Share
SXTP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $207.9K | +106% |
| Q1 2026 | $162.1K | -0.9% |
| Q4 2025 | $303.4K | +31% |
| Q3 2025 | $437.6K | +223% |
| Q2 2025 | $100.9K | -19% |
| Q1 2025 | $163.6K | +40% |
| Q4 2024 | $230.8K | +84% |
| Q3 2024 | $135.3K | +164% |
SXTP's revenue is growing: $207,898 last quarter, up 106% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1092% | +498 points |
| Q1 2026 | -1292% | -124 points |
| Q4 2025 | -632% | +267 points |
| Q3 2025 | -531% | +1035 points |
| Q2 2025 | -1590% | +1762 points |
| Q1 2025 | -1168% | -25 points |
| Q4 2024 | -899% | +608 points |
| Q3 2024 | -1566% | +1407 points |
SXTP's operating margin was −1092% last quarter, up 498 points from the same quarter a year ago.
SXTP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.2M | -$734.3K |
| Q1 2026 | -$2.8M | -$1.2M |
| Q4 2025 | -$1.8M | -$134.1K |
| Q3 2025 | -$2.1M | -$424.1K |
| Q1 2025 | -$1.6M | -$459.6K |
| Q4 2024 | -$1.6M | -$1.5M |
SXTP has burned cash in almost every quarter: −$9M over the past year, against −$6M the year before.
SXTP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +54% | +928K shares |
| 1 year | +727% | +2.3M shares |
SXTP has 3M diluted shares, up 727% from a year ago.
SXTP Net Leverage
SXTP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SXTP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.7 | Neutral |
| Stochastic | 13.1 | Oversold |
SXTP's weekly RSI is 32 (neutral) and its Stochastic is 13 (oversold).
SXTP PE vs Healthcare Sector
SXTP has no meaningful PE right now: it lost money over the past year.
SXTP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 43% below |
| 20 week MA | $1.10 | 53% below |
| 50 week MA | $1.86 | 72% below |
| 100 week MA | $5.62 | 91% below |
SXTP is in a downtrend: it's below all four of its weekly moving averages, and 91% below its 100-week average.
SXTP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $916.8 | $244.8 | -73% |
| 2024 | $244.8 | $25.8 | -89% |
| 2025 | $25.8 | $2.78 | -89% |
| 2026 YTD | $2.78 | $0.52 | -81% |
SXTP has finished every year since 2023 lower, and it's down 81% so far in 2026.